Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Slides:

Advertisements

Similar presentations

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.

Advertisements

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Christopher C. Miller, Christopher A

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Cystic fibrosis research in allied health and nursing professions

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

Felix Ratjen, Paul Koker, David E

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Defining antimicrobial resistance in cystic fibrosis

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Controlled clinical trials in cystic fibrosis — are we doing better?

Inhaled aztreonam lysine vs

Community-acquired pneumonia: the evolving challenge

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Valerie Waters, Eshetu G

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Eradication of early P. aeruginosa infection in children

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Gautham Marigowda, Fang Liu, David Waltz Journal of Cystic Fibrosis

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

CFTR modulators and pregnancy: Our work has only just begun

Journal of Cystic Fibrosis

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection J. Stuart Elborn, Patrick A. Flume, Fredric Cohen, Jeffery Loutit, Donald R. VanDevanter Journal of Cystic Fibrosis Volume 15, Issue 5, Pages 634-640 (September 2016) DOI: 10.1016/j.jcf.2016.01.005 Copyright © 2016 Terms and Conditions

Fig. 1 Study design. Abbreviations: BID, twice daily; LIS, levofloxacin inhaled solution; RCT, randomized control trial [10]; TIS, tobramycin inhalation solution. Journal of Cystic Fibrosis 2016 15, 634-640DOI: (10.1016/j.jcf.2016.01.005) Copyright © 2016 Terms and Conditions

Fig. 2 Patient disposition. Abbreviations: AE, adverse event; LIS, levofloxacin inhaled solution 240mg twice daily; TIS, tobramycin inhalation solution 300mg twice daily. Journal of Cystic Fibrosis 2016 15, 634-640DOI: (10.1016/j.jcf.2016.01.005) Copyright © 2016 Terms and Conditions

Fig. 3 Relative changes in FEV1% predicted from RCT baseline to day 336. On the left are data from the intent-to-treat population of the RCT [10]; on the right are those subjects who received ≥1 dose of LIS in the extension. Complete data from only those patients who participated in the extension study may be seen in Fig. S2. Error bars indicate standard error. Abbreviations: LIS, levofloxacin inhaled solution 240mg twice daily; TIS, tobramycin inhalation solution 300mg twice daily. Journal of Cystic Fibrosis 2016 15, 634-640DOI: (10.1016/j.jcf.2016.01.005) Copyright © 2016 Terms and Conditions